TY - JOUR
T1 - The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors
AU - Tocchetti, Carlo G.
AU - Gallucci, Giuseppina
AU - Coppola, Carmela
AU - Piscopo, Giovanna
AU - Cipresso, Clemente
AU - Maurea, Carlo
AU - Giudice, Aldo
AU - Iaffaioli, Rosario V.
AU - Arra, Claudio
AU - Maurea, Nicola
PY - 2013/5
Y1 - 2013/5
N2 - Left ventricular dysfunction from anticancer drugs has emerged as a relevant problem in the clinical and scientific communities. Anthracycline toxicity has always been the most relevant, but with the increasing use of biological targeted therapies in treatment protocols, with an increasing number of cancer survivors, new toxicities have been increasing in more recent years. Cardiomyopathy after ErbB2 inhibitors has been intensively studied. Another important class of biological anticancer drugs are vascular endothelial growth factor (VEGF) inhibitors. VEGF signalling is crucial for vascular growth, but it also has a major impact on myocardial function. Also, it is important to note that such angiogenesis inhibitors are multitargeted in most cases, and can produce a broad spectrum of cardiovascular side effects. Here we review the mechanisms and pathophysiology of the most significant cardiotoxic effects of antiangiogenic drugs, and particular attention is drawn to LV dysfunction, discussing the assessment and management on the basis of the most recent cardio-oncological findings and heart failure guidelines. All rights reserved.
AB - Left ventricular dysfunction from anticancer drugs has emerged as a relevant problem in the clinical and scientific communities. Anthracycline toxicity has always been the most relevant, but with the increasing use of biological targeted therapies in treatment protocols, with an increasing number of cancer survivors, new toxicities have been increasing in more recent years. Cardiomyopathy after ErbB2 inhibitors has been intensively studied. Another important class of biological anticancer drugs are vascular endothelial growth factor (VEGF) inhibitors. VEGF signalling is crucial for vascular growth, but it also has a major impact on myocardial function. Also, it is important to note that such angiogenesis inhibitors are multitargeted in most cases, and can produce a broad spectrum of cardiovascular side effects. Here we review the mechanisms and pathophysiology of the most significant cardiotoxic effects of antiangiogenic drugs, and particular attention is drawn to LV dysfunction, discussing the assessment and management on the basis of the most recent cardio-oncological findings and heart failure guidelines. All rights reserved.
KW - Anti-angiogenic drugs
KW - Cardiovascular risk factors
KW - Hypertension
KW - Left ventricular dysfunction
KW - Multitargeted tyrosine kinase inhibitors
KW - VEGF
UR - http://www.scopus.com/inward/record.url?scp=84877153703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877153703&partnerID=8YFLogxK
U2 - 10.1093/eurjhf/hft008
DO - 10.1093/eurjhf/hft008
M3 - Article
C2 - 23325019
AN - SCOPUS:84877153703
VL - 15
SP - 482
EP - 489
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
SN - 1388-9842
IS - 5
ER -